Evidence map›Paper›PMID 37679646›Full record

ArticleBone marrow transplantation2023

Thrombopoietin level predicts the response to avatrombopag treatment for persistent thrombocytopenia after haploidentical haematopoietic stem cell transplantation.

Haixia Fu, Meng Lv, Huixin Liu, Yuqian Sun, Yuanyuan Zhang, Xiaodong Mo, Tingting Han, Fengrong Wang, Chenhua Yan, Yu Wang and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 1 institution in 2 countries.

Haixia FuPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Meng LvPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Huixin LiuPeking University People's Hospital, Department of Clinical Epidemiology and Biostatistics, Beijing, China.
Yuqian SunPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Yuanyuan ZhangPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Xiaodong MoPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Tingting HanPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Fengrong WangPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Chenhua YanPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Yu WangPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.ORCID http://orcid.org/0000-0003-1253-7465
Jun KongPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Wei HanPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Huan ChenPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Yao ChenPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Yuhong ChenPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Lanping XuPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.ORCID http://orcid.org/0000-0002-0267-1081
Kaiyan LiuPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Xiaojun HuangPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China.
Xiaohui ZhangPeking University People's Hospital, Peking University Institute of Haematology, Beijing, China. zhangxh@bjmu.edu.cn.ORCID http://orcid.org/0000-0003-4730-256X
Peking University · CN

Funding

Capital Health Research and Development of Special 2022-1-4082National Natural Science Foundation of China (National Science Foundation of China) 81970113Natural Science Foundation of Beijing Municipality (Beijing Natural Science Foundation) 7232188
6 · The paper itself

Abstract

Persistent thrombocytopenia (PT) has an unsatisfactory response to therapy after haploidentical haematopoietic stem cell transplantation (haplo-HSCT). We retrospectively evaluated the safety and efficacy of avatrombopag treatment in 69 patients with PT following haplo-HSCT and assessed whether baseline thrombopoietin (TPO) levels could predict treatment response. Overall response (OR) and complete response (CR) were defined as increased platelet levels to over 20 × 10

Indexed as

Hematopoietic Stem Cell TransplantationThrombocytopeniaHumansRetrospective StudiesThiazolesThiophenesThrombopoietinavatrombopagThiazolesThiophenesThrombopoietin

Identifiers

PMID37679646
OpenAlexW4386513395

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.